Dr. John Cush RheumNow
2 years 5 months ago
JAMA Review of DMARD Use in Rheumatoid Arthritis
JAMA has reviewed the "2022 EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs".
https://t.co/pJLriraWqq https://t.co/JElMzDyeMs
Dr. John Cush RheumNow
2 years 5 months ago
COX-2 (on the left) have lower ulcer risk than COX-1 (to the right) NSAIDs. @BCryer https://t.co/Xfm7xJkvzd
Dr. John Cush RheumNow
2 years 5 months ago
High risk pts on NSAIDs need prophylaxis!! @bcryer https://t.co/NAnHtkTNvL
Dr. John Cush RheumNow
2 years 5 months ago
Endoscopy and Worry are indicated in the face of DYSPEPSIA and any of these: @BCryer https://t.co/6TabKhiLPO
Dr. John Cush RheumNow
2 years 5 months ago
Testing for H. Pylori. Serologic tests are OK but after Rx eradication, 25% of pts will remain positive for H. Pylori. @BCryer
Dr. John Cush RheumNow
2 years 5 months ago
Multiple Rx options to treat H. Pylori - Dr. Cryer recs regimens of 14ds; top line w/ bismuth is most recommended. (most effective is the one the patient will actualy take!) @BCryer https://t.co/f6836Ga1Fz
Dr. John Cush RheumNow
2 years 5 months ago
H. Pylori is usually acquired during childhood, remains dormant until activated years later. Is assoc w/ PUD and gastric cancer, not dyspepsia. Baylor Univ Grand Round By Dr. Byron Cryer @BCryer https://t.co/KXZfigVYX9
Dr. John Cush RheumNow
2 years 5 months ago
Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women
https://t.co/u2cf5hmTAE https://t.co/A4kdwG6eRm
Dr. John Cush RheumNow
2 years 5 months ago
JAK-pot: 46913 Rx courses on JAKi, TNFi, other MOA. Rx D/Cs for AEs:
- TNFi = JAKi (HR 1.0)
- Other MOA > JAKi (HR 1.11)
- TNFi < tofacitinib (0.81)
- TNFi > baricitinib (1.15)
- TNFi < JAKi; if >65yrs w/ CV risk (0.79) https://t.co/N5XnPjxAXO https://t.co/AnoKM7fzM7
Dr. John Cush RheumNow
2 years 5 months ago
What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review the challenges of these conditions. https://t.co/EqJRXSzrEs https://t.co/z5yuHDXUZ3
Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui.
Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics.
Dr. John Cush RheumNow
2 years 5 months ago
Effective Treatments for Still's Disease
A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy of tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK).
https://t.co/Qi98OXyoLJ https://t.co/DCgXfs0Bot
Dr. John Cush RheumNow
2 years 5 months ago
Depression and RA
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week.
https://t.co/nJZD4D2ByC https://t.co/ET3Xp9cK62
Dr. John Cush RheumNow
2 years 5 months ago
Vaccinations NOT linked to SLE risk. 17 studies (45 million) w/ F/U up to 2 yrs. No signif SLE risk:
- all vaccinations (OR=1.1; CI 0.86–1.5)
- HBV vax (OR=2.11; 1.11-4)
- HPV (OR=1.4; 0.88–2.3)
- Flu (OR=0.96; 0.82–1.1)
- COVID (OR=0.44; 0.18–1.2) https://t.co/YpxSYL97DM https://t.co/hsytm9UpDC
